[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632891":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":13,"id":55,"slug":13,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":13,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":13,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":13,"overallStatus":73,"whyStopped":13,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Occurrence of adverse events","Incidences of adverse events","Up to week 60",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":13,"interventionNames":24},"CM512","EXPERIMENTAL",[25],"Biological: CM512",[27],{"type":28,"name":22,"description":29,"armGroupLabels":30,"otherNames":13},"BIOLOGICAL","Administered subcutaneous injection",[22],[32],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[38],{"facility":39,"status":13,"city":40,"state":13,"zip":13,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing Tong-Ren hospital","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":52,"phoneExt":13,"email":36},"Luo Zhang","010-58268486-8009",{"type":54,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100632891",false,"NCT07519577","A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）","An Open-Label, Single-Arm, Multicenter, Extension Study to Evaluate the Safety and Efficacy of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis","Inclusion Criteria:\n\n* Participated in the clinical study of CM512 in patients with Chronic Rhinosinusitis with Nasal Polyposis (Study No. of CM512-102101) .\n\nExclusion Criteria:\n\n* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy\u002Fsystemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.\n* Administration of a live attenuated vaccine within 30 days prior to baseline or planning to receive one during the study period.","ALL","18 Years","75 Years",{"count":65,"type":66},120,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis",[72],"Chronic Rhinosinusitis With Nasal Polyposis","NOT_YET_RECRUITING","2026-06-26",{"date":76,"type":77},"2026-06-30","ACTUAL",{"date":79,"type":66},"2026-05-31",{"date":81,"type":66},"2028-05-31",{"name":5,"class":6},1]